ARID1A and ovarian clear cell cancer: Most ARID1A mutations are inactivating truncating mutations [46]—e.g., 63% of ARID1A gene alterations in urothelial carcinomas [30] or over 90% of ARID1A mutations in ovarian clear cell carcinoma [47].